FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064533488> ?p ?o ?g. }

• W2064533488 endingPage "347" @default.
• W2064533488 startingPage "347" @default.
• W2064533488 abstract "Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK Sobha Sivaprasad, Nachiketa Acharya, Phil HykinMoorfields Eye Hospital, London, UKAbstract: The pathogenesis of age-related macular degeneration (AMD) is unclear, but it can take either a neovascular/exudative/wet form, characterized by choroidal neovascularization (CNV), or a dry form. No treatments are available for the dry form, but there are a number of pharmacological interventions that inhibit vascular endothelial growth factor (VEGF), which is central to the pathogenesis of CNV and neovascular AMD. Available anti-VEGF agents either target all active VEGF isoforms (eg, ranibizumab), or take a more selective approach and inhibit only VEGF165 (eg, pegaptantib sodium). Current guidance on their use is equivocal and restrictive at best, resulting in associated difficulties in securing adequate, timely funding for treatment. The Moorfields Eye Hospital undertook an audit of 70 patients receiving intravitreal (ITV) pegaptanib sodium on a pro re nata (prn) dosing schedule. Despite initial funding delays, the audit recorded superior treatment outcomes compared with those reported in the VISION trials at 12 weeks: 88% of audit patients maintained stable vision, 29% gained vision and 6% experienced severe vision loss compared with 70%, ≥6% and ≤10% of patients in VISION at 54 weeks, respectively. The audit indicates a positive correlation between patients with better baseline visual acuity (VA) and improved therapeutic benefits, including a greater likelihood of both vision gain and vision preservation. Experience at Moorfields also suggests that pegaptanib sodium is more useful in occult lesions than minimally classic lesions, and clinical experience suggests that combination therapies may offer the best approach with anti-VEGF therapies. Further randomized clinical trials will help better determine the optimal treatment strategies with pegaptanib sodium in neovascular AMD.Keywords: age-related macular degeneration, choroidal neovascularization, vascular endothelial growth factor, pegaptanib sodium, visual outcomes, funding" @default.
• W2064533488 created "2016-06-24" @default.
• W2064533488 creator A5000602717 @default.
• W2064533488 creator A5066434934 @default.
• W2064533488 creator A5089799800 @default.
• W2064533488 date "2008-06-01" @default.
• W2064533488 modified "2023-10-17" @default.
• W2064533488 title "Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK" @default.
• W2064533488 cites W1522421496 @default.
• W2064533488 cites W1970302814 @default.
• W2064533488 cites W1972242350 @default.
• W2064533488 cites W1981608508 @default.
• W2064533488 cites W1982345261 @default.
• W2064533488 cites W2006646315 @default.
• W2064533488 cites W2015655380 @default.
• W2064533488 cites W2037780881 @default.
• W2064533488 cites W2039446733 @default.
• W2064533488 cites W2042321005 @default.
• W2064533488 cites W2049825753 @default.
• W2064533488 cites W2058775052 @default.
• W2064533488 cites W2079843091 @default.
• W2064533488 cites W2084098837 @default.
• W2064533488 cites W2085712747 @default.
• W2064533488 cites W2086585123 @default.
• W2064533488 cites W2099024510 @default.
• W2064533488 cites W2101421486 @default.
• W2064533488 cites W2111078506 @default.
• W2064533488 cites W2123617249 @default.
• W2064533488 cites W2124415048 @default.
• W2064533488 cites W2184824787 @default.
• W2064533488 cites W2262759767 @default.
• W2064533488 cites W2298362195 @default.
• W2064533488 cites W2598520882 @default.
• W2064533488 cites W303397638 @default.
• W2064533488 cites W1511911088 @default.
• W2064533488 doi "https://doi.org/10.2147/opth.s2601" @default.
• W2064533488 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2693996" @default.
• W2064533488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19668726" @default.
• W2064533488 hasPublicationYear "2008" @default.
• W2064533488 type Work @default.
• W2064533488 sameAs 2064533488 @default.
• W2064533488 citedByCount "1" @default.
• W2064533488 countsByYear W20645334882016 @default.
• W2064533488 crossrefType "journal-article" @default.
• W2064533488 hasAuthorship W2064533488A5000602717 @default.
• W2064533488 hasAuthorship W2064533488A5066434934 @default.
• W2064533488 hasAuthorship W2064533488A5089799800 @default.
• W2064533488 hasBestOaLocation W20645334881 @default.
• W2064533488 hasConcept C118487528 @default.
• W2064533488 hasConcept C119767625 @default.
• W2064533488 hasConcept C141071460 @default.
• W2064533488 hasConcept C162324750 @default.
• W2064533488 hasConcept C187736073 @default.
• W2064533488 hasConcept C199521495 @default.
• W2064533488 hasConcept C2776403814 @default.
• W2064533488 hasConcept C2776694085 @default.
• W2064533488 hasConcept C2777512022 @default.
• W2064533488 hasConcept C2777802072 @default.
• W2064533488 hasConcept C2778257484 @default.
• W2064533488 hasConcept C2780699112 @default.
• W2064533488 hasConcept C2781100027 @default.
• W2064533488 hasConcept C2781359195 @default.
• W2064533488 hasConcept C71924100 @default.
• W2064533488 hasConceptScore W2064533488C118487528 @default.
• W2064533488 hasConceptScore W2064533488C119767625 @default.
• W2064533488 hasConceptScore W2064533488C141071460 @default.
• W2064533488 hasConceptScore W2064533488C162324750 @default.
• W2064533488 hasConceptScore W2064533488C187736073 @default.
• W2064533488 hasConceptScore W2064533488C199521495 @default.
• W2064533488 hasConceptScore W2064533488C2776403814 @default.
• W2064533488 hasConceptScore W2064533488C2776694085 @default.
• W2064533488 hasConceptScore W2064533488C2777512022 @default.
• W2064533488 hasConceptScore W2064533488C2777802072 @default.
• W2064533488 hasConceptScore W2064533488C2778257484 @default.
• W2064533488 hasConceptScore W2064533488C2780699112 @default.
• W2064533488 hasConceptScore W2064533488C2781100027 @default.
• W2064533488 hasConceptScore W2064533488C2781359195 @default.
• W2064533488 hasConceptScore W2064533488C71924100 @default.
• W2064533488 hasLocation W20645334881 @default.
• W2064533488 hasLocation W20645334882 @default.
• W2064533488 hasLocation W20645334883 @default.
• W2064533488 hasLocation W20645334884 @default.
• W2064533488 hasOpenAccess W2064533488 @default.
• W2064533488 hasPrimaryLocation W20645334881 @default.
• W2064533488 hasRelatedWork W2000167025 @default.
• W2064533488 hasRelatedWork W2024548441 @default.
• W2064533488 hasRelatedWork W2034093159 @default.
• W2064533488 hasRelatedWork W2046686346 @default.
• W2064533488 hasRelatedWork W2054981704 @default.
• W2064533488 hasRelatedWork W2068871928 @default.
• W2064533488 hasRelatedWork W2121621777 @default.
• W2064533488 hasRelatedWork W2233259956 @default.
• W2064533488 hasRelatedWork W2682124582 @default.
• W2064533488 hasRelatedWork W2599281049 @default.
• W2064533488 isParatext "false" @default.
• W2064533488 isRetracted "false" @default.
• W2064533488 magId "2064533488" @default.
• W2064533488 workType "article" @default.